United Kingdom

Profile: Anika Therapeutics Inc (ANIK.OQ)

ANIK.OQ on NASDAQ Stock Exchange Global Select Market

8:13pm BST
Change (% chg)

$0.77 (+2.07%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Anika Therapeutics, Inc., incorporated on February 28, 1992, is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company's therapeutic offerings consist of products in the areas, including Orthobiologics, Dermal, Surgical, and Other, which includes the Company's ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.


The Company's orthobiologics products primarily consist of viscosupplementation and regenerative orthopedic products. These products are used in a range of treatments, from providing pain relief from osteoarthritis to regenerating damaged tissue, such as cartilage. The Company's viscosupplementation franchise includes ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL. ORTHOVISC is available in the United States, Canada, and other international markets for the treatment of osteoarthritis of the knee, and in Europe and certain international markets for the treatment of osteoarthritis in all joints. ORTHOVISC mini is available in Europe, and it is designed for the treatment of osteoarthritis in small joints. MONOVISC is its single injection osteoarthritis treatment indicated for all joints in Europe and certain international markets, and for the knee in the United States, Turkey, and Canada. The Company offers CINGAL as a viscoelastic supplement or as a replacement for synovial fluid in human joints.

In the United States, ORTHOVISC is indicated for the treatment of pain caused by osteoarthritis of the knee. ORTHOVISC is a sterile, clear, viscous solution of hyaluronan dissolved in physiological saline and dispensed in a single-use syringe. In the United States, MONOVISC is also indicated for the treatment of pain caused by osteoarthritis of the knee. MONOVISC is a sterile, clear, viscous solution of partially cross-linked sodium hyaluronate in a phosphate buffered saline solution.

The Company offers several additional products used in connection with orthopedic regenerative medicine. These products are based on the HYAFF technology and are available in Europe, South America, and Asia. They include HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a graft wrap; and HYALOSS MATRIX, HYAFF fibers used to mix blood/bone grafts to form a paste for bone regeneration. The Company also offers HYALOGLIDE, an ACP gel used in tenolysis treatment, with the potential for use in flexor tendon adhesion prevention and for use in the shoulder for prevention of adhesive capsulitis with additional clinical data. This product is commercialized through a network of distributors, primarily in Europe, the Middle East, and Korea. In addition to these products, it received Conformite Europeene (CE) Mark approval for a product, which utilizes its HA technology to treat pain associated with lateral epicondylitis, known as tennis elbow.


The Company's dermal products consist of wound care products, based on the HYAFF technology, and an aesthetic dermal filler, based on its chemically modified cross-linked HA technology. Products utilizing its HYAFF technology are used for the treatment of skin wounds, ranging from burns to diabetic ulcers. The products cover a range of wound treatment solutions, including debridement agents, therapies to aid healing, and scaffolds used as skin substitutes. The Company's products include HYALOMATRIX and HYALOFILL, for the treatment of complex wounds, such as burns and ulcers. The dermal products are commercialized through a network of distributors, primarily in the United States, Europe, Latin America, and the Middle East. The Company also offers HYALOMATRIX, HYALOFILL, HYALOGRAN, and HYALOMATRIX 3D in the United States.


The Company's surgical business consists of products used to prevent post-surgical adhesions after abdominal-pelvic, spinal, and ear, nose, and throat (ENT) surgeries. HYALOBARRIER is a post-operative adhesion barrier for use in the abdominopelvic area. The product is commercialized in Europe, the Middle East, and certain Asian countries through a distribution network. HYALOSPINE is a product designed to prevent post-surgical adhesions following spinal surgery. INCERT, approved for sale and commercialized through a network of distributors in Europe, Turkey, and Malaysia, is a chemically modified, cross-linked HA product, for the prevention of spinal post-surgical adhesions.


The Company's other products include its ophthalmic and veterinary products. The Company's ophthalmic business includes injectable, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation. These products coat, lubricate, and protect sensitive tissue, such as the endothelium, and they function to maintain the shape of the eye, thereby facilitating ophthalmic surgical procedures. The Company's veterinary product, HYVISC, is a high molecular weight injectable HA product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine osteoarthritis. HYVISC has viscoelastic properties that lubricate and protect the tissues in horse joints.

Company Address

Anika Therapeutics Inc

32 Wiggins Ave
BEDFORD   MA   01730-2315
P: +1781.4579000
F: +1781.3059720

Company Web Links